The specific recognition of foreign peptide bound to the major histocompatibility complex (MHC) molecule by T-cell receptor (TCR) leads to T-cell activation. We found that analogue peptides containing single amino acid substitutions at the third amino acid position (p3), p5, p7 and p8 of the index peptide (YWALEAAAD) induced different response patterns of T cell clones specific for the index peptide in the context of the human MHC class II molecule HLA-DR4. Analogue peptides were classified into three types, agonists, antagonists or null peptides (nonagonistic and non-antagonistic peptides). A molecular basis for how these slight changes lead to such different consequences for T cells has not been described. To explore the mechanistic basis of these observations, molecular dynamics simulations at 300 K of 300 ps duration were carried out for the DR4-index peptide, DR4-agonist, and DR4-antagonist complexes. The simulations showed that the DR4-antagonist complexes were distinguished from the DR4-index peptide and DR4-agonist complexes by relatively higher deviations of C α atoms in proposed TCRbinding regions, suggesting that subtle changes of the exposed framework of the peptide binding groove by the antagonist peptides could induce the TCR antagonistic activities.
Introduction
Major histocompatibility complex (MHC) class II molecules on the cell surface present peptide antigens to T cells in the generation of an immune response. The CD4 ϩ Th cells are activated on recognition of short peptides complexed with the MHC molecule by T cell receptor (TCR) and proliferate to exert effector functions through various biologic activities of secreted lymphokines. Recent studies of altered peptide ligands carrying amino acid substitutions at TCR-contact residues on the antigenic peptides revealed that some of such peptides induced T cell nonresponsiveness through TCR antagonism or anergy induction as a consequence of partial or incomplete activation (De Magistris et al., 1992; Sloan-Lancaster et al., 1993; Kersh and Allen, 1996a,b; Chen et al., 1996; Matsuoka et al., 1996; Dittel et al., 1997) . How can a ligand that differs very slightly from an agonist deliver a unique signal to the T cell? The kinetics model has been proposed to answer this question (Matsui et al., 1994) . In this model, TCR has a reduced affinity for analogue-HLA complexes as compared with the agonist-HLA complex. This results in a reduction in the time that TCR remains engaged with its ligand, that is, it has a faster off-rate for the altered ligand than the agonist. A short interaction with the peptide-MHC ligand then results in a qualitatively different signal through the TCR (McKeithan, 1995; Rabinowitz et al., 1996) . The structural basis of the reduced affinity is explained by subtle local changes of crystal structures of HLA class I molecule complexed with altered peptide (Reid et al., 1996) .
We used HLA-DR4 allotype DRB1*0405, peptide YWALE-AAAD (Y ϭ position 1, p1), and a T cell clone which responds to this complex as a model system to examine the molecular mechanisms of agonistic or antagonistic activities. In this system, analogue peptides carrying single residue substitutions at p3, p5, p7 or p8 were used and T cell response experiments with synthetic analogue peptides carrying single residue substitutions in the index peptide (YWALEAAAD) exhibited a set of agonistic peptides, antagonistic peptides and null (nonagonistic and non-antagonistic) peptides.
According to crystallographic analysis of peptides associated with HLA-DR1, HLA-DR3, HLA-DR4 (DRB1*0401) and I-E k (a murine class II MHC molecule) (Stern et al., 1994; Ghosh et al., 1995; Fremont et al., 1996; Jardetzky et al., 1996; Murthy and Stern, 1997; Dessen et al., 1997) , MHC class II molecules may generally constrain bound peptides to a regular polyproline II-like conformation, where the C β atoms at p5 and p8 are completely exposed to solvent and the side chain at p7 at least partially buried in a shallow pocket. The p3 side chain is exposed to solvent on a shelf-like pocket.
The molecular dynamics (MD) simulation technique allows one to elucidate the atomic details of structural transitions and the detailed dynamics behaviour of protein, if input coordinates and calculation parameters are carefully selected. The MD simulations of MHC-peptide complexes have been carried out (Rognan et al., 1992a (Rognan et al., ,b, 1994 (Rognan et al., , 1995 (Rognan et al., , 1997 . In this article, molecular models of the HLA-DRB1*0405-index and HLA-DRB1*0405-analogue peptide (agonists and antagonists) complexes were developed by MD simulations and minimum energy calculations to predict molecular mechanism of the observed T cell reactivities. The results were compared with those from simulations of the DR4-index peptide complex. Our simulations suggested that antagonistic peptides cause local conformational changes on the surface of the DR4 molecule which could be sufficient to affect the TCR recognition.
Materials and methods

Preparation of the input coordinates
All simulations were performed using the Insight II/Discover Software Package (Molecular Simulations, Inc., San Diego, CA). In terms of sequence identity, HLA-DRB1*0405 is closely related to HLA-DRB1*0401, and because the structure of DRB1*0401 has already been analysed using X-ray crystallography, starting coordinates were taken from the crystal structure of the DR4-collagen peptide complex as a template (Dessen et al., 1997; Protein Data Bank entry 2SEB) . Hydrogen atoms were added to this model using the Insight II program. To save computational time, only the antigenbinding site (α3-α84, β3-β94) was taken into account in the study. This approximation was shown not to alter significantly the three-dimensional structure of the α1-β1 region because only limited interactions exist between the α1-β1 and α2 or β2 domains, which are not thought to contact antigenic peptides in the binding groove (Rognan et al., 1992a) . The DRB1*0405-collagen peptide complex was constructed by replacement of two DRβ residues (DRβ57 and DRβ71) that differ between DRB1*0401 and DRB1*0405. A peptide (NH 2 -AAYWA-LEAAADAA-COOH) and all analogue peptides bound to DRB1*0405 molecule were similarly generated from the backbone of the bound collagen peptide (residues 1168-1180), QYMRADQAAGGLR, co-crystallized with DRB1*0401 by substituting by corresponding residues. After that, 1000 steps of energy minimization with the steepest descent method were applied, using a 15.0 Å cut-off and a distance-dependent dielectric function.
Molecular mechanics and dynamics simulation protocol
The parameter used was the consistent valence force field (CVFF). No cross-terms were used in the energy expression and a simple harmonic valence potential was used to model the valence bond stretching term. The minimized structures were solvated by a 10.0 Å layer of water molecules using the SOAK option of Insight II. The CVFF water potential resembles those of the SPC and TIP3P models (Lau et al., 1994) . During the molecular dynamics and minimization, a dielectric constant of 1.0 was used. A twin range cut-off (12 and 15 Å) was applied to calculate van der Waals and electric interactions. A 15.0 Å cut-off was calculated once every 20 time steps and the remaining 19 steps were calculated with a 12.0 Å cut-off. Since the use of switching functions may introduce artefacts into the simulation properties, switching functions were not employed in any of the simulations (Arnold and Ornstein, 1994; Paulsen and Ornstein, 1995) . Before the MD simulations were started, we performed energy minimizations in a four-step procedure: (i) the coordinates of the all protein atoms were fixed and solvent molecules were minimized using the steepest descent method (in all constrained minimizations for up to 1000 iterations). (ii) The heavy chain atoms were tethered loosely (10 kcal mol -1 Å -2 ) while the hydrogen atoms were adjusted. (iii) The backbone atoms were tethered loosely (10 kcal mol -1 Å -2 ) while the side chain was adjusted. (iv) Finally, the conjugated gradient minimizations were performed with all atoms free to move until the maximum derivative was Ͻ0.5 kcal mol -1 Å -1 . The minimized coordinates were used as a starting point for NVT (constant volume and temperature) molecular dynamics at 300 K to generate possible stable conformations. The system was warmed to 300 K. After a 10 ps equilibration stage, the simulations were continued at 300 K for 290 ps using a 1.0 fs time step. The simulations were carried out using the Verlet leapfrog algorithm and the structures were stored in the computer every 1.0 ps. Solvent-accessible surface areas Accessible and buried surface areas were calculated for MD mean structures. The Connolly algorithm with a solvent probe radius of 1.4 Å was used (Connolly, 1983) . Transfectants One pair of HLA class II DR4 (DRA*0102/DRB1*0405) α and β genes were co-transfected with PAG60 harbouring a 1028 neomycin-resistant gene into a mouse L fibroblast cell line, Ltk -, as described previously (Kamikawaji et al., 1991) . Peptide synthesis Peptides were synthesized using a 396MPS multiple peptide synthesizer (Advanced ChemTech, Louisville, Kentucky), using standard F-moc amino acids with DIC/HOBt coupling chemistry on the polystyrene resin. Peptides were cleaved from the resin with trifluoroaceticacid (TFA) containing 1% ethanedithiol, 3% anisole and 3% ethylmethylsulfide. The cleaved peptides were washed with ether, and were frozen dry in 10% acetic acid.
Generation of T cell lines
A T cell clone generated from a homozygote of DRB1*0405 with allogeneic (DRB1*08032) lymphocytes was proliferated with KEAYWALEAAADAEK complexed with self DRB1* 0405 molecule. This T cell clone was used as a model system to investigate recognition of MHC-peptide complexes by the TCR. According to the binding motif of DRB1*0405, YWALEAAAD is a core peptide binding to the DRB1*0405 molecule. T cell proliferation assay T cell response experiments with synthetic analogues, in which a single amino acid of the index peptide was substituted, were examined. The T cell clone was assayed by culturing the cells (4ϫ10 4 /well) in 96-well flat-bottom culture plates in the presence or absence of synthetic peptide using mitomycin C (MMC) treated L-cell transfectants (3.5ϫ10 4 /well) in a total volume of 200 µl (Kamikawaji et al., 1991) with the index peptide and analogue peptides. Cells were cultured for 72 h in the presence of 1 mCi/well of 3 [H]-methyl thymidine (ICN Biomedicals, Costa Mesa, CA) for the last 12 h. Cells were harvested on glass fibre filters (Wallac, Turku, Finland), and the incorporated radioactivity was quantified by a liquid scintillation counter (Wallac).
Results
Determination of residues critical for activation of an HLA-DRB1*0405 restricted T cell clone
We established T cell clones from homozygotes of HLA-DR4 by stimulation of allogeneic DR8 positive irradiated PBL. One of the T cell clones proliferated in the presence of DR4 (self HLA molecule) expressing transfectant with peptide YWALEAAAD. According to the previously reported binding motifs for HLA-DRB1*0405 associated peptides (Kinouchi et al., 1994; Matsushita et al., 1994; Rammensee et al., 1995) , residues at position 1 (p1), p4, p6 and p9 were anchor residues and p2, p3, p5, p7 and p8 were exposed to solvent. We further examined the cross reactivity of the T cell clone to the mimicry epitope by a set of peptides in which amino acids of the mimicry epitope YWALEAAAD were substituted. Adopting the criterion whereby amino acids at each position were allowed when their peptide analogues activated the T cell clones at 5 µM, a molecular mimicry motif that activates the T cell clone in the context of self DR4 HLA molecule was identified (Table I ). The critical role of the glutamic acid residue at p5 for the interaction between the TCR and DR4-peptide complex is clear as only the p5-Glu peptide activated the T cell clone at 0.5 µM, whereas peptides with any other amino acids at p5 failed to activate the T cell clone even at a 100-fold increase in concentration (50 µM). The Glu at p5 was shown to be the most critical determinant for activation of the T cell clone in the context of DRB1*0405. The T cell clone accepts both conservative and nonconservative substitutions at p8, indicating that p8 was not the predominant TCR contact site.
To evaluate the effects of single amino acid substitutions in the sequence of the index peptide on T cell responses, proliferation of the T cell clone that recognizes the index peptide bound to HLA-DR4 was tested in the presence of various concentrations of the analogue peptides. Based on the results of this investigation, we classified the analogue peptides into three groups, agonists, antagonists or null peptide (nonagonistic and non-antagonistic peptides) (Table I) . When the analogue peptides were found to suppress proliferative responses of the T cell clone, we defined the analogue peptides as 'antagonists'.
Definition of putative TCR-binding regions
Knowing the structure of a TCR complexed with a class I MHC molecule bound to a peptide (Garboczi et al., 1996; Garcia et al., 1996 Garcia et al., , 1998 Ding et al., 1998) , questions about the orientation of TCR on the MHC-peptide ligand complex can be generalized to all TCR interactions with class I molecules, and perhaps with class II MHC molecule as well (Jorgensen et al., 1992; Sant'Angelo et al., 1996; Chang et al., 1997) . The long axis of the TCR and MHC molecules are not quite parallel to one another but tilted by approximately 20 to 40 degrees. The TCR avoids high points and fits at low points on the MHC surface to contact the length of the exposed peptide (Bjorkman, 1997) . Genetic analysis of class II MHCrestricted TCR offered a common TCR docking orientation utilized by TCR regardless of MHC restriction (Sant'Angelo et al., 1996; Chang et al., 1997) . Molecular modelling of a TCR-peptide-MHC class II (I-E k ) complex predicted residues on the MHC molecule which interact with the TCR (Almagro et al., 1995) . Thus, helical regions (α55, α57, α61, α62, α64, α65, α67, α68, β63, β64, β66, β70, β73, β77 , β81 and β85) of α and β chains were defined as the putative TCR-binding regions (Figure 1 ).
Molecular dynamics simulations of DR4-agonist and DR4-antagonist complexes
To understand the basis for the observed phenomena, we simulated some DR4 (DRB1*0405)-analogue peptide complexes based on the coordinates generated from the HLA-DR4 (DRB1*0401) crystal structure (Dessen et al., 1997) . A gross overview of MD simulation is provided by root mean squared (r.m.s.) deviation plots. R.m.s. positional deviations of the C α atoms of DR4-peptide complexes from the starting structure Fig. 1 . Putative TCR-binding regions on the DR4 molecule: gray balls, C α atoms of selected residues as the putative TCR-contacting sites; black ball, C α atom of p5-Glu. The DR4 molecule and antigenic peptide are indicated by the C α trace: α-chain, thin line: β-chain, bold line: peptide, white bold line. The TCR-contact sites were defined as follows: α55 Glu, α57 Gln, α61 Ala, α62 Asn, α64 Ala, α65 Val, α67 Lys, α68 Ala, β63 Ser, β64 Gln, β66 Asp, β70 Gln, β73 Ala, β77 Thr, β81 His and β85 Val. Molecular graphics figures in this paper were generated using the MOLSCRIPT program (Kraulis, 1991). reached a plateau at about 1.3 Å but were still drifting slightly (Figure 2 ). Acquired data were analysed during the last 50 ps of the 300 ps simulation. Initially, we defined an average atomic conformation of the DR4-index peptide (YWALEAAAD) complex during the last 50 ps of the simulation as an 'index complex'.
RMS atomic deviations of DR4-analogue peptide complexes
In the proposed TCR-binding regions on the DR4 molecule, r.m.s. deviations for the C α traces between the index complex and DR4-analogue peptide (p3, p5, p7 and p8) complexes were computed. In the antagonist complexes, the deviations were higher than those of the agonist complexes (Figure 3 ). In the both agonist and antagonist complexes, a network of hydrogen bonds between HLA-DR4 and the analog peptides were similar.
In the simulations of the p7-Val (an antagonist for the T cell) complex, the calculated r.m.s. deviations were relatively higher than the p3-antagonist and p8-antagonist complexes ( Figure 3B ). Solvent-accessible surface areas were computed for the time-averaged conformations between 250 and 300 ps. In the index, p7-Gly and p7-Phe complexes, the p7 side chain was buried in the pocket (less than 4% of residue exposure). In the p7-Val complex, however, the p7 side chain was more accessible to solvent (about 40% residue exposure). The p7-Val side chain which could not fit into pocket 7 moved up and interacted with the side chain of Gln β64 and Leu β67 on the β1 helix. Thus, small shifts occurred in the location of the β1 helix between residues β60 and β68. In the p3-antagonist complexes, the location of the α-chain α-helix between residues α54 and α58 differed from that in the index complex. The p3 side chain which could not fit into the small pocket 3 was solvent exposed and caused a small shift of the α1 helix. In the simulations of the p8-variants, the calculated r.m.s. deviations were lower than those of the p3-, p7-and p5-variants. A wider range (0.6-1.2 Å) of C α deviations of the p8-antagonist complexes was observed throughout the simulation.
The Glu side chain at p5 is the major contact site for TCR and the T cell clone is very sensitive to substitutions at p5. Even a conservative mutation of p5 from Glu to Asp in the index peptide generates a weak antagonist peptide (Table I) . Then we simulated the p5-Asp and p5-Gly (a weak agonist) complexes. In the p5-Asp complex, the deviations in the TCRrecognition regions were relatively higher (1.4-1.8 Å) than those of the p3-, p7-and p8-antagonists complexes. In the time-averaged structure of the p5-Asp complexes, the helical region between residues α53 and α61 collapsed and moved closer to the peptide. A simulation of the p5-Gly complex exhibited relatively lower deviations of the C α atoms (0.6-0.8 Å) than those of the p3-, p7-and p8-agonist complexes ( Figure 3D ).
Discussion
The mechanistic basis of TCR antagonism is still unknown. In a model system developed for analysing the specific features of the T cell clone that recognizes the index peptide presented by a DR4 molecule, we performed MD simulations of some DR4-analogue peptide (agonist and antagonist) complexes. Our analysis demonstrates that antagonistic peptides substituted at p3, p5, p7 or p8 could cause structural changes in the proposed TCR-contact regions of the DR4 molecule.
In our model system, the T cell clone could require absolute amino acid identity at p5 and the analogue peptide, with a conservative Glu to Asp change, would be recognized by the T cell clone as a different determinant. The Glu side chain at p5 of the index peptide would be accommodated in a deep pocket at the centre of the TCR. The p5 side chain projects out of peptide-binding site and is fully exposed to solvent, but even the Glu to Asp change induced main chain shifts of the α1 helix. The p8 side chain also projects into solvent, but the calculated r.m.s. deviations of the p8-antagonist complexes were lower than those of the p5-Asp complex ( Figure 3B and  D) . These effects demonstrated that the solvent-exposed p5 residue can greatly influence the exposed structure of the peptide-binding groove. Though the Glu to Gly change at p5 could hardly trigger conformational changes ( Figure 3D ), the p5-Gly complex is a weak agonist because of the small nonpolar side chain of p5. In addition to direct changes in charge and shape at p5, the potent effects of the p5 side chain result in most analogue peptides (nine of 12 p5-variants) being null ligands (Table I) .
Substitutions of p7 tend to have relatively larger influence to alter conformations of the putative TCR-contact regions during the simulations than those of p3 and p8 (Figure 3 ). Replacements at p7 are able to cause major conformational shifts of the β-chain helix, because the side chain at p7 is partially buried in a smaller pocket in DR4 than DR1. Although 10 of 20 analogue peptides at p7 are classified into null peptides which may be treated as completely different ligands with large conformational changes, the p8 variants are divided into two classes, agonists or antagonists (Table I ). The simulations are in agreement with these experimental data describing the more potent effects of replacements at p7.
In the p8-variants, the calculated r.m.s. deviations were lower than those of the p3-, p7-and p5-variants, indicating that the substitutions of p8 have less potent effects on the exposed framework of DR4. A wider range of C α deviations of the p8-antagonist complexes from the index complex suggests that the p8-antagonists induce various conformational changes of the TCR-recognition sites on the DR4 molecule. The various structural changes may cause differences in affinity between the TCR and p8-antagonist complexes and be sufficient to induce TCR antagonist activities.
The p3 side chain except Ala and Gly is exposed to TCR contacts on a shelf-like pocket in DR1 and DR3 (Stern et al., 1994; Ghosh et al., 1995; Murthy and Stern, 1997) . In the p3-antagonists, the p3 side chain (Val and Pro) was not able to fit into the small pocket 3 and caused small shifts of the α1 helix. The p3 side chain except Ala and Gly would cause small changes of the α1 helix and induce TCR antagonism (14 of 20 p3-variants). A long side chain at p3 (Lys, Arg and Tyr) may be highly exposed to TCR contacts and be null ligands for the TCR (Table I) .
These simulations suggest that subtle conformational changes in the TCR-binding sites of the DR4 molecule could induce TCR antagonistic activities. Subtypes of HLA-DR4 are strongly associated with autoimmune diseases. Our observations may be useful to search for analogue peptides that down-1031 regulate autoimmunity by exerting antagonistic activity for TCR in human T cells.
